Clinical Trial Update: NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of NFX-179 topical gel for adults with Neurofibromatosis type 1 and cutaneous neurofibromas has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Neurofibroma
• Neurofibromatosis Type

Drugs mentioned

• NFX-179 topical gel (NFX-179)

Snippet

Sponsor: NFlection Therapeutics, Inc. | Conditions: Neurofibromatosis 1, Cutaneous Neurofibroma | Phase 2 | Status: COMPLETED | Results posted: 2022-08-09